» Articles » PMID: 38933416

An Artificial Signaling Pathway Primitive-based Intelligent Biomimetic Nanoenzymes Carrier Platform for Precise Treatment of Her2 (+) Tumors

Overview
Journal Mater Today Bio
Date 2024 Jun 27
PMID 38933416
Authors
Affiliations
Soon will be listed here.
Abstract

In tumor treatment, the deposition of nanoenzymes in normal tissues and cause potential side effects are unavoidable. Here, we designed an intelligent biomimetic nanoenzymes carrier platform (MSC) that endows the carrier platform with "wisdom" by introducing Affibody-Notch(core)-VP64-GAL4/UAS-HSV-TK artificial signal pathways to mesenchymal stem cells (MSCs). This intelligent nanoenzymes carrier platform is distinguished from the traditional targeting tumor microenvironment or enhancing affinity with tumor, which endue MSC with tumor signal recognition capacity, so that MSC can autonomously distinguish tumor from normal tissue cells and feedback edited instructions. In this study, MSC can convert tumor signals into HSV-TK instructions through artificial signal pathway after recognizing Her2 (+) tumor. Subsequently, the synthesized HSV-TK can rupture MSC under the mediation of ganciclovir, and release the preloaded Cu/Fe nanocrystal clusters to kill the tumor accurately. Meanwhile, MSC without recognizing tumors will not initiate the HSV-TK instructions, thus being unresponsive to GCV and blocking the release of nanoenzymes in normal tissues. Consequently, MSC is the first intelligent biomimetic nanoenzymes carrier platform, which represents a new biomimetic nanoenzymes targeting mode.

Citing Articles

Targeted regulation of autophagy using sorafenib-loaded biomineralization nanoenzyme for enhanced photodynamic therapy of hepatoma.

Lu T, Liu Z, Qian R, Zhou Y, Li J, Zhang Q Mater Today Bio. 2024; 29:101270.

PMID: 39403315 PMC: 11472109. DOI: 10.1016/j.mtbio.2024.101270.

References
1.
Mitri Z, Constantine T, ORegan R . The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2013; 2012:743193. PMC: 3539433. DOI: 10.1155/2012/743193. View

2.
Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View

3.
Du W, Liu T, Xue F, Cai X, Chen Q, Zheng Y . FeO Mesocrystals with Distinctive Magnetothermal and Nanoenzyme Activity Enabling Self-Reinforcing Synergistic Cancer Therapy. ACS Appl Mater Interfaces. 2020; 12(17):19285-19294. DOI: 10.1021/acsami.0c02465. View

4.
Xuan M, Shao J, Dai L, Li J, He Q . Macrophage Cell Membrane Camouflaged Au Nanoshells for in Vivo Prolonged Circulation Life and Enhanced Cancer Photothermal Therapy. ACS Appl Mater Interfaces. 2016; 8(15):9610-8. DOI: 10.1021/acsami.6b00853. View

5.
Wu Y, Soslow R, Marshall D, Leitao M, Chen B . Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol. 2004; 95(3):570-5. DOI: 10.1016/j.ygyno.2004.08.043. View